GM3 and insulin sensitivity

Conditions: Diabetes
Insulin resistance
10018424

Registration Number: NL-OMON32641

Lead Sponsor: Academisch Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 20

Inclusion Criteria

- written informed consent
- Caucasian
- able to keep a normal day and night rhythm during the study period (i.e. no shift work)
- stable weight for at least 3 months
- age 20-55 years
AND Inclusion criteria for healthy volunteers:
- 20 * BMI * 25 kg/m2
- fasting glucose level of < 5.6 mmol/L, in addition to a glucose level of < 7.8 mmol/L at 2 hours after intake of 75 g glucose (OGTT).;OR Inclusion criteria for obese subjects:
- BMI >30 kg/m2
- fasting glucose level of < 7 mmol/L, in addition to a glucose level of < 11.0 mmol/L at 2 hours after intake of 75 g glucose (OGTT).
- HOMA IR > 2.7

Exclusion Criteria

- participation in an investigational drug trial within 90 days prior to our study
- history of or current abuse of drugs or alcohol (>14 U/week)
- smoking
- vigorous physical activity
- family history of DM II
- familial dyslipidemia
- any medical condition except hypertension and dyslipidemia in the obese group
- use of any medication except for anti-hypertensives, excluding ACE-inhibitors/AII-antagonists

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Peripheral insulin sensitivity<br /><br>- GM3 concentration in skeletal muscle and abdominal adipose tissue<br /><br></p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- plasma concentration of glucoregulatory hormones<br /><br>- energy expenditure<br /><br>- carbohydrate oxidation and fat oxidation<br /><br>- VO2 max<br /><br>- Muscle fiber type</p><br>